Detalles de la búsqueda
1.
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Haematologica
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38654660
2.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol
; 102(10): 2741-2752, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592092
3.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976398
4.
Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
Acta Haematol
; : 1-8, 2023 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37848002
5.
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.
Transfus Med Hemother
; 50(6): 475-490, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38089497
6.
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.
Transfus Med Hemother
; 50(5): 403-416, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37899991
7.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431518
8.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
9.
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood
; 136(7): 823-830, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32496541
10.
Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices.
Acta Haematol
; 145(6): 603-610, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35908542
11.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer
; 149(11): 1935-1943, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310714
12.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33154570
13.
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Acta Haematol
; 143(3): 217-231, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590170
14.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047142
15.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032641
16.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575024
17.
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
BMC Cancer
; 16(1): 936, 2016 12 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27919243
18.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549589
19.
Palliative treatment of colorectal cancer with secondary metastasis resection in Germany - impact of the multidisciplinary treatment approach on prognosis and cost: the Northern Bavaria IVOPAK I Project.
Oncology
; 88(2): 103-21, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25341688
20.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940